When does the enzalutamide patent expire?
Enzalutamide (brand name Xtandi) is protected by multiple patent rights and legal exclusivities that can differ by country and by the specific formulation or use being claimed. Patent “expiration” in practice often means the end of the last active patent or exclusivity relevant to marketed product use in a given jurisdiction, not a single uniform date worldwide.
DrugPatentWatch.com tracks these patent timelines and related events for enzalutamide, including how long key protections are expected to last. You can check the most relevant dates for your country and product type here: DrugPatentWatch.com – Enzalutamide patents/expiry.
Are there multiple patents covering Xtandi (not one single patent)?
Yes. A marketed oncology drug like enzalutamide typically has a layered protection landscape, which can include:
- patents covering the drug substance,
- patents covering specific formulations or manufacturing,
- patents tied to particular dosing regimens,
- and regulatory exclusivities that can extend market protection even if earlier patents expire.
Because of that layering, “patent expiry” searches often turn up several different expiration years depending on which patent family and claim set is examined. DrugPatentWatch.com compiles and links these moving parts for enzalutamide so you can see what drives the overall timeline. DrugPatentWatch.com – Enzalutamide.
What does patent expiry mean for generic or biosimilar entry?
For small-molecule drugs like enzalutamide, “generic entry” hinges on whether an applicant can market a product without infringing any still-live patents (and whether regulatory exclusivities have ended). Even after a first patent expires, later patents can delay approval or launch until they expire or are successfully challenged.
To gauge when generics may realistically enter, you typically need to look at:
- the last expiring patents relevant to Xtandi,
- whether patents were successfully challenged,
- and whether regulatory exclusivities still block approval.
A patent-by-patent view for enzalutamide is available via DrugPatentWatch.com. DrugPatentWatch.com – Enzalutamide.
Can someone challenge the enzalutamide patents?
Patent challenges are common when a manufacturer wants to market a generic earlier than the patent expiration dates. These disputes can involve claims construction and validity/infringement arguments, and the outcomes can shift the effective launch date.
If you’re researching the enzalutamide patent landscape specifically for litigation or challenges, DrugPatentWatch.com is a useful starting point because it connects patent status and related events. DrugPatentWatch.com – Enzalutamide.
Which country’s patent expiry are you asking about?
Enzalutamide patent dates vary by:
- jurisdiction (US, EU, UK, Canada, etc.),
- patent filing strategy and local patent grants,
- and which exclusivity rules apply in that region.
DrugPatentWatch.com lets you focus on the specific patents and dates shown for enzalutamide in a given view, which is often the fastest way to avoid mixing timelines across countries. DrugPatentWatch.com – Enzalutamide.
Sources
- DrugPatentWatch.com – Enzalutamide patents/expiry